PSMA-PET Imaging for Advanced ACC/SDC

Status Completed

Clinical Trial Summary

Diagnostic study which evaluates the level of PSMA expression in patients with locally advanced, recurrent and/or metastatic ACC/SDC of ≥18 years old with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy

Clinical Trial Description

Rationale: PSMA is a transmembrane protein, which is expressed on prostate cancers cells, ACC and other malignancies. In prostate cancer, distant metastases can be visualized sensitively and non-invasively with 68Ga-PSMA-PET/CT scans and if the uptake of 68Ga is high enough, patients can be treated with the β-emitting radionuclide 177Lu-PSMA. In the current study, we will evaluate the uptake of 68Ga-PSMA by performing 68Ga-PSMA-PET/CT scans in advanced ACC and SDC patients. If the uptake is high enough, this will form the rationale for a therapeutic study with 177Lu-PSMA in ACC and SDC.

Objective: The primary objective is to evaluate the uptake of 68Ga-PSMA in locally advanced, recurrent and metastatic ACC/SDC by performing 68Ga-PSMA-PET/CT scans. The secondary objectives are to calculate the SUV tumor-to-background ratio and tumor-to-'healthy salivary gland tissue' ratio. To correlate the SUV to the degree of immunohistochemical PSMA expression of the primary tumor on archival tissue, and to establish whether new metastatic lesions are found by 68GA-PSMA-PET/CT imaging.

Study design: Diagnostic study which evaluates the level of PSMA expression in ACC/SDC patients with 68Ga-PSMA-PET/CT imaging in order to establish whether these patients are eligible for 177Lu-PSMA therapy.

Study population: Patients with locally advanced, recurrent or metastatic ACC/SDC of ≥18 years old. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03319641
Study type	Interventional
Source	Radboud University
Contact
Status	Completed
Phase	N/A
Start date	October 25, 2017
Completion date	May 14, 2018

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04973683` - AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer	Phase 1
Completed	`NCT01417143` - Dovitinib in Adenoid Cystic Carcinoma	Phase 2
Recruiting	`NCT04140526` - Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC	Phase 1/Phase 2
Active, not recruiting	`NCT05010629` - 9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma	Phase 2
Recruiting	`NCT04801264` - Diagnosis of Adenoid Cystic Carcinoma on 68Ga-PSMA-617 PET-CT and Therapy With 177Lu-EB-PSMA-617	Early Phase 1
Recruiting	`NCT02942693` - Trail Evaluating Particle Therapy With or Without Apatinib for H&N Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT00581360` - Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck	Phase 2
Not yet recruiting	`NCT05553782` - Drug Screening Using Novel IMD in ACC and Salivary Cancers	Early Phase 1
Completed	`NCT04291300` - Lutetium-177-PSMA Radioligand Therapy in Advanced Salivary Gland Cancer Patients	Phase 2
Active, not recruiting	`NCT02775370` - A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck	Phase 2
Active, not recruiting	`NCT02780310` - Testing Lenvatinib in Patients With Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT04119453` - A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)	Phase 2
Active, not recruiting	`NCT02098538` - Regorafenib in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT01524692` - Study of Dovitinib (TKI258) in Adenoid Cystic Carcinoma	Phase 2
Completed	`NCT01558661` - Axitinib (AG-013736) in Patients With Progressive, Recurrent/Metastatic Adenoid Cystic Carcinoma	Phase 2
Recruiting	`NCT03556228` - Selective TrkA Inhibitor VMD-928 to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma	Phase 1
Recruiting	`NCT01192087` - Adenoid Cystic Carcinoma, Erbitux, and Particle Therapy	Phase 1/Phase 2
Recruiting	`NCT04209660` - Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers	Phase 2
Recruiting	`NCT05774899` - CB-103 With Either Lenvatinib or Abemaciclib in Patients With NOTCH ACC	Phase 1/Phase 2
Completed	`NCT01152840` - Study of RAD001 in Adenoid Cystic Carcinoma	Phase 2